01—Abstract
Summary
Summary of the 8-K filed November 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics reported a strong third quarter of 2026, with total revenue growing 39% year-over-year to $493 milliona and royalty revenue increasing by 44% to $341 million.
This robust performance has prompted the company to raise its full-year 2026 financial guidance across key metrics including total revenue, royalty revenue, Adjusted EBITDA, and Non-GAAP Diluted EPS. The company also highlighted significant progress in its ENHANZE® collaboration agreements, expanding partnerships with three current collaborators and advancing three ENHANZE® programs into Phase 1 clinical development.
A notable legal victory was also achieved, with a Dutch patent court ruling in favor of Halozyme in an infringement case against Merck concerning its Keytruda Qlex product, leading to an injunction in several European markets. The company further strengthened its financial position by completing a $1.5 billionb convertible notes offering.
02—Key points
Key Highlights
- Total revenue for Q3 2026 reached $493 million, a 39% increase year-over-year.
- Royalty revenue saw a significant 44% year-over-year increase to $341 million in Q3 2026.
- Halozyme has raised its full-year 2026 financial guidance for total revenue, royalty revenue, Adjusted EBITDA, and Non-GAAP Diluted EPS.
- Three ENHANZE® collaboration agreements were expanded with current partners, and three ENHANZE® programs advanced to Phase 1 clinical development.
- A Dutch patent court ruled in favor of Halozyme, finding Merck infringing a key patent and issuing an injunction against Keytruda Qlex in multiple European markets.
- The company successfully completed a $1.5 billion convertible notes offering, enhancing financial flexibility.
- Halozyme repurchased approximately $67.2 million of its common stock in Q3 2026 as part of its 2026 share repurchase program, totaling $400 million year-to-date.
03—Questions
Frequently Asked Questions
What is the primary driver behind Halozyme's significant revenue growth?
The primary driver for Halozyme's revenue growth is the continued sales uptake of ENHANZE® partner products that have launched since 2020, notably VYVGART® Hytrulo, DARZALEX® SC, and Phesgo. This is reflected in the substantial increase in royalty revenue.
What is the significance of the legal ruling against Merck?
The ruling from the Dutch patent court is significant because it validates one of Halozyme's key patents and grants an injunction prohibiting the launch of Merck's Keytruda Qlex in several European markets. This reinforces the company's intellectual property rights and protects its revenue streams derived from its ENHANZE® technology.
How does the company's updated financial guidance reflect its performance?
The company's decision to raise its full-year 2026 financial guidance for total revenue, royalty revenue, Adjusted EBITDA, and Non-GAAP Diluted EPS indicates strong confidence in its business trajectory. It signifies that Halozyme is exceeding its previous expectations and is on track for robust financial performance in the current fiscal year.
What is the impact of the recent convertible notes offering?
The completion of the $1.5 billion convertible notes offering strengthens Halozyme's financial position by providing increased flexibility. This allows the company to execute its capital allocation strategy, including reinvesting in growth opportunities and managing its debt obligations.
04—Continue